UTHR (United Therapeutics) Float Percentage Of Total Shares Outstanding: 85.48% (As of Jun. 29, 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $548.00
GF Value $386.40
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Float Percentage Of Total Shares Outstanding?

United Therapeutics UTHR +1.05% 88 Float Percentage Of Total Shares Outstanding is 85.48% as of Jun. 29, 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.40 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, United Therapeutics's float shares is 36.29 Mil. United Therapeutics's total shares outstanding is 42.45 Mil. United Therapeutics's float percentage of total shares outstanding is 85.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, United Therapeutics's Insider Ownership is 0.40%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, United Therapeutics's Institutional Ownership is 108.57%.

UTHR
88GF Score
United Therapeutics Corp UTHR
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

United Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=36.29/42.45
=85.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 85.48% mean?
United Therapeutics (UTHR) has a Float Percentage Of Total Shares Outstanding of 85.48% as of Jun. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Float Percentage Of Total Shares Outstanding too high?
United Therapeutics' current Float Percentage Of Total Shares Outstanding is 85.48%. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Float Percentage Of Total Shares Outstanding compare to VTRS and NBIX?
United Therapeutics' Float Percentage Of Total Shares Outstanding of 85.48% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on United Therapeutics and its competitors. United Therapeutics's current Float Percentage Of Total Shares Outstanding is 85.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.40, compared to a current price of $548.00 — trading 41.8% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 85.48%. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Float Percentage Of Total Shares Outstanding is 85.48% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $548.00 is trading 41.8% above its estimated GF Value™ of $386.40. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Float Percentage Of Total Shares Outstanding: 85.48%
  • GF Value™: $386.40 vs. price of $548.00 (41.8% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$548.00
Price
$386.40
GF Value